These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8045919)

  • 1. Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Keizer HJ; De Bruijn EA; Tjaden UR; De Clercq E
    J Cancer Res Clin Oncol; 1994; 120(9):545-9. PubMed ID: 8045919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo.
    Desgranges C; Razaka G; Drouillet F; Bricaud H; Herdewijn P; De Clercq E
    Nucleic Acids Res; 1984 Feb; 12(4):2081-90. PubMed ID: 6701093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antitumor potency of oral tegafur against adenocarcinoma 755 in mice is markedly enhanced by oral (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Iigo M; Yamaizumi Z; Nishimura S; Hoshi A; De Clercq E
    Jpn J Cancer Res; 1987 Apr; 78(4):409-13. PubMed ID: 3108221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice.
    Iigo M; Nakajima Y; Hoshi A; De Clercq E
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):773-7. PubMed ID: 3115784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on life-span and 5-fluorouracil metabolism in mice with hepatic metastases.
    Iigo M; Nishikata K; Nakajima Y; Hoshi A; De Clercq E
    Eur J Cancer; 1990; 26(10):1089-92. PubMed ID: 2148885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice.
    Desgranges C; Razaka G; De Clercq E; Herdewijn P; Balzarini J; Drouillet F; Bricaud H
    Cancer Res; 1986 Mar; 46(3):1094-101. PubMed ID: 3943086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deoxyribosyl exchange reactions leading to the in vivo generation and regeneration of the antiviral agents (E)-5-(2-bromovinyl)-2'-deoxyuridine, 5-ethyl-2'-deoxyuridine and 5-(2-chloroethyl)-2'-deoxyuridine.
    Desgranges C; De Clercq E; Razaka G; Drouillet F; Belloc I; Bricaud H
    Biochem Pharmacol; 1986 May; 35(10):1647-53. PubMed ID: 3011010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of E-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil on herpes simplex virus replication and DNA synthesis.
    Descamps J; Sehgal RK; De Clercq E; Allaudeen HS
    J Virol; 1982 Jul; 43(1):332-6. PubMed ID: 6287008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.
    De Clercq E
    Biochem Pharmacol; 2004 Dec; 68(12):2301-15. PubMed ID: 15548377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
    De Clercq E
    Med Res Rev; 2005 Jan; 25(1):1-20. PubMed ID: 15389733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (E)-5-(2-bromovinyl)uridine requires phosphorylation by the herpes simplex virus (type 1)-induced thymidine kinase to express its antiviral activity.
    Bernaerts R; Desgranges C; De Clercq E
    Biochem Pharmacol; 1989 Jun; 38(12):1955-61. PubMed ID: 2545207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of (E)-5-(2-bromovinyl)-2'-deoxyuridine in plasma and urine by capillary electrophoresis.
    Olgemöller J; Hempel G; Boos J; Blaschke G
    J Chromatogr B Biomed Sci Appl; 1999 Apr; 726(1-2):261-8. PubMed ID: 10348194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
    Balzarini J; Sienaert R; Liekens S; Van Kuilenburg A; Carangio A; Esnouf R; De Clercq E; McGuigan C
    Mol Pharmacol; 2002 May; 61(5):1140-5. PubMed ID: 11961132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutual kinetic interaction between 5-fluorouracil and bromodeoxyuridine or iododeoxyuridine in dogs.
    Smith DE; Brenner DE; Knutsen CA; Deremer SJ; Terrio PA; Johnson NJ; Stetson PL; Ensminger WD
    Drug Metab Dispos; 1993; 21(2):277-83. PubMed ID: 8097697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Allaudeen HS; Kozarich JW; Bertino JR; De Clercq E
    Proc Natl Acad Sci U S A; 1981 May; 78(5):2698-702. PubMed ID: 6265902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-(5-Bromothien-2-yl)-2'-deoxyuridine and 5-(5-chlorothien-2-yl)-2'-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2'-deoxyuridine in the inhibition of herpes simplex virus type I replication.
    Wigerinck P; Pannecouque C; Snoeck R; Claes P; De Clercq E; Herdewijn P
    J Med Chem; 1991 Aug; 34(8):2383-9. PubMed ID: 1652017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil].
    Watabe T; Okuda H; Ogura K
    Yakugaku Zasshi; 1997 Nov; 117(10-11):910-21. PubMed ID: 9414600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients.
    Wildiers J; De Clercq E
    Eur J Cancer Clin Oncol; 1984 Apr; 20(4):471-6. PubMed ID: 6539202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Harris SA; McGuigan C; Andrei G; Snoeck R; De Clercq E; Balzarini J
    Antivir Chem Chemother; 2001 Sep; 12(5):293-300. PubMed ID: 11900348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.
    Van Der Heyden SA; Highley MS; De Bruijn EA; Tjaden UR; Reeuwijk HJ; Van Slooten H; Van Oosterom AT; Maes RA
    Br J Clin Pharmacol; 1999 Apr; 47(4):351-6. PubMed ID: 10233196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.